Current Perspectives on the NF-κB Signaling Axis as a Potential Pharmacological Target in Cardiorenal Syndrome

Area of Science:

• Cardiorenal medicine
• Molecular biology
• Pharmacology

Background:

• Cardiorenal syndrome (CRS) is a complex, life-threatening condition affecting the heart and kidneys.
• Current treatments for CRS are limited due to its rapid progression and high mortality rate.
• Nuclear factor kappa-B (NF-κB) plays a key role in inflammation and oxidative stress in both cardiac and renal tissues.

Purpose of the Study:

• To review the role of NF-κB in CRS.
• To explore the potential of NF-κB inhibition as a novel therapeutic strategy for CRS.
• To identify natural compounds with dual NF-κB inhibitory effects on cardiac and renal tissues.

Main Methods:

• Comprehensive review of preclinical and clinical research on CRS.
• Analysis of the structure and function of NF-κB in cardiovascular and renal systems.
• Identification of natural compounds targeting NF-κB.

Main Results:

• NF-κB is mechanistically involved in the pathogenesis of CRS.
• NF-κB inhibition demonstrates potential cardiorenal protective effects.
• Natural compounds capable of dual NF-κB inhibition in cardiac and renal tissues were identified.

Conclusions:

• Targeting NF-κB offers a novel therapeutic avenue for CRS.
• Dual NF-κB inhibitors may provide concurrent protection to the heart and kidneys.
• Further research into NF-κB-targeted pharmacology is crucial for developing new CRS treatments.